Project Grant R01MH137075
- This Cooperative Agreement award, provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), aims to enhance clinical prediction for individuals with serious mental illness (SMI). The key products and services to be delivered under this $18,270,924 award, with a performance period from September 10, 2025 to September 9, 2029, include: Recruiting 1,500 participants across five inpatient psychiatry units at McLean Hospital to...
- The National Institute of Mental Health (NIMH) awarded a $447,132 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Empathy Rocks Inc. in Bellevue, WA. The project, titled "Standardizing COA Administration with AI Technology: Ensuring Consistency and Accuracy in Clinical End Points," aims to develop an AI-powered tool that will provide standardized, real-time quality oversight for the administration and scoring of clinical outcome assessments (COAs) used in...
- This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to develop a low-cost, objective system for monitoring psychosis severity using automated speech and language analysis. The $845,163 award, effective August 1, 2025, will support the implementation and evaluation of novel deep learning approaches to adapt predictive models for each individual patient, producing personalized markers of concurrent...
- The National Institute of Mental Health (NIMH) awarded a $183,118 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to advance precision psychiatry research. The award period runs from September 1, 2025 to August 31, 2029. The key objectives of this grant are to: (1) derive etiological insights into clinically-relevant psychiatric phenotypes and build translational models to...
- This federal Project Grant award of $185,123.00 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support research to enhance the semantic representation of mental, behavioral, and social phenomena. The primary goal is to improve outcomes for people living with mental health conditions by enabling researchers, clinicians, and consumers to leverage computational methods and clinical decision support technologies. The project...
- The National Institute of Mental Health (NIMH) awarded a $627,600 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Miresource, Inc. The grant will fund the development of an integrated software solution to improve longitudinal mental health monitoring and generate personalized mental health guides and referrals for patients. The project aims to address gaps in mental health treatment access and timeliness by providing patients with a scalable and engaging method...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $380,104 to Drexel University to rapidly improve the efficacy of precision psychiatry digital health interventions. The key products and services to be delivered include: Developing real-world, person-centered maintenance models for psychopathology using ecological data and dynamic systems modeling. This will involve...
- The National Institute of Mental Health (NIMH) awarded a $854,029 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop and evaluate a multimodality adaptive intervention for reducing suicide risk in the critical three-month period following inpatient psychiatric hospitalization. The key products and services to be delivered through this 5-year grant, which commenced on...
- The federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), is providing $1,392,638 to support a hybrid effectiveness/implementation cluster randomized trial to evaluate a single session intervention (SSI) and interpersonal therapy for adolescent depression in Mozambican primary care clinics. The project aims to address the critical mental health treatment gap for adolescents in low- and middle-income...
- This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $850,462 to Weill Medical College of Cornell University to study integrated care delivery for dual-eligible individuals with serious mental illness (SMI). The key objectives are to assess how enrollment in Integrated Dual-Eligible Special Needs Plans (D-SNPs) impacts healthcare utilization, quality, and mortality among this high-need population (Aims...
PERSONALIZED QUALITY OF LIFE MEASUREMENT - PROJECT SUMMARY/ABSTRACT. A LACK OF OUTCOME-FOCUSED QUALITY MEASURES IS HOLDING BACK MENTAL HEALTH (MH) PROGRESS. THIS GAP MEANS THAT REGULATORY BODIES AND THIRD-PARTY PAYERS DO NOT HAVE A "COMMON DENOMINATOR" THAT THEY CAN USE TO COMPARE THE IMPACT OF MH SYMPTOMS AND TREATMENT OPTIONS ACROSS ALL MH AND PHYSICAL HEALTH (PH) CONDITIONS. FOR EXAMPLE, WE CANNOT EFFECTIVELY COMPARE THE OVERALL IMPACT OF TREATMENT FOR DEPRESSION TO TREATMENT FOR OTHER MH CONDITIONS SUCH AS SCHIZOPHRENIA, OR TO PH CONDITIONS SUCH AS DIABETES. QUALITY MEASUREMENT ALSO UNDERPINS COST-EFFECTIVENESS RESEARCH, AND AS A RESULT WE CANNOT ACCURATELY ALLOCATE RESOURCES NEEDED FOR A NATIONWIDE MH STRATEGY. FURTHERMORE, CLINICIANS AND RESEARCHERS CANNOT RECOMMEND TREATMENTS BASED ON OVERALL IMPACT, BUT RATHER THEY ARE RESTRICTED TO NARROWLY FOCUSED SYMPTOM AND OUTCOME MEASUREMENTS. WITHOUT ADDRESSING PROBLEMS IN OUTCOME-FOCUSED QUALITY MEASURES, PATIENTS WILL CONTINUE TO FACE A DISJOINTED MH CARE SYSTEM WHERE SUFFICIENT RESOURCES ARE NOT APPORTIONED TO THEIR NEEDS, THEIR CLINICIANS CANNOT SELECT TREATMENTS IN A WAY THAT WILL MAXIMIZE THEIR OVERALL FUNCTIONING, AND RESEARCH TO IMPROVE THEIR CARE CANNOT CONSISTENTLY DEMONSTRATE COMPARATIVE EFFECTIVENESS. QUALITY OF LIFE (QOL) MEASURES PROVIDE A PROMISING APPROACH TO SERVE AS A COMMON DENOMINATOR FOR OUTCOME- FOCUSED QUALITY MEASUREMENT ACROSS CONDITIONS. HOWEVER, CURRENT NOMOTHETIC APPROACHES ARE NOT SPECIFIC TO MH SYMPTOMS, WHICH CREATES MEASUREMENT INSENSITIVITY AND SUBSTANTIALLY REDUCES MEASUREMENT ACCURACY. THERE ARE ALSO MANY IDIOGRAPHIC QOL MEASURES THAT ARE TAILORED TO SPECIFIC DISORDERS, BUT THEY ARE NOT DIRECTLY COMPARABLE ACROSS MH OR PH CONDITIONS. NEW QOL MEASUREMENT APPROACHES ARE NEEDED THAT ARE BOTH NOMOTHETICALLY COMPARABLE ACROSS DISEASE CONDITIONS AND IDEOGRAPHICALLY TAILORED TO MH PHENOMENOLOGY. NEW DEVELOPMENTS IN UNSUPERVISED MACHINE LEARNING (ML) ARE WELL SUITED TO ADDRESS THESE LIMITATIONS IN QOL MEASUREMENT. SPECIFICALLY, WE WILL USE RECENT ADVANCES IN MIXTURE MODELING TO CREATE A NEW PERSONALIZED QOL MEASUREMENT APPROACH THAT SIMULTANEOUSLY PRODUCES BOTH NOMOTHETIC AND IDIOGRAPHIC RESULTS. THE PROPOSED PROJECT IS SIGNIFICANT AND IMPACTFUL BECAUSE IT ELIMINATES A CRITICAL BOTTLENECK TO EFFORTS BY POLICY MAKERS, RESEARCHERS, AND CLINICIANS. RESULTS FROM THIS WORK WILL ALLOW ALL OF THESE STAKEHOLDERS TO BETTER DISCERN DIFFERENTIAL IMPACT AMONG MH CONDITIONS AND INTERVENTIONS. AS A RESULT, THEY WILL BE ABLE TO BETTER SERVE PATIENTS WHO EXPERIENCE MH DIFFICULTIES. THIS PROJECT IS ALSO SCIENTIFICALLY AND METHODOLOGICALLY INNOVATIVE. IT CREATIVELY USES NEW DEVELOPMENTS IN UNSUPERVISED ML TO IMPLEMENT A NEW MEASUREMENT PROCESS WHILE MINIMIZING DISRUPTION TO CURRENT PRACTICES. OVERALL, THE PROPOSED PROJECT WILL PROVIDE A NEW STANDARD FOR OUTCOME-FOCUSED MEASUREMENT OF MH CARE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $561.4k | 8/20/25 | ||
| Not listed | $447.2k | 7/25/24 |